Healthy Japanese subjects
Conditions
Interventions
Duration: Four weeks Test food: Capsule containing AHCC Administration: Take three capsules with water after each meal. In total nine capsules a day, taken three times daily. *If you forget to ta
Sponsors
ORTHOMEDICO Inc.
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy subjects 5. Subjects who have complaints related to post-COVID-19 central symptoms after completion of cure (e.g., breath difficulty, cough, palpitations, lassitude, malaise, headache, fluffy dizziness, insomnia, depression, decline in thought, hair loss, other skin symptoms, vertigo, loss of smell, or loss of taste (discomfort in the mouth and throat) {whose "Degree of Symptoms (score)" are one point or more in all of "Major Symptoms" as listed in the consultation checklist for patients with post-COVID-19 symptoms}) 6. Subjects whose "Degree of Symptoms (score)" are two points or more in one or more of the corresponding "Major Symptoms" as listed in the consultation checklist for patients with post-COVID-19 symptoms 7. Subjects whose "Degree of Symptoms (score)" are three points or less in all of "Major Symptoms" as listed in the consultation checklist for patients with post-COVID-19 symptoms
Exclusion criteria
Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who suffered from diseases (e.g., lifestyle disease, cardiac diseases, cancer, or respiratory diseases) except for post-COVID-19 symptoms after recovery from COVID-19 5. Subjects who have been diagnosed with post-COVID-19 symptoms 6. Subjects who use or take "Foods for Specified Health Uses," or "Foods with Functional Claims" in daily 7. Subjects who are currently taking medications (including herbal medicines) and supplements 8. Subjects who are allergic to medicines and/or the test food related products 9. Subjects who are pregnant, lactating, or planning to become pregnant during this trial 10. Subjects who suffer from COVID-19 11. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 12. Subjects who are judged as ineligible to participate in this study by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The proportion of subjects whose "Degree of Symptoms (score)" decrease by one point or more in one or more of the corresponding "Major Symptoms" as listed in the consultation checklist for patients with post-COVID-19 symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The subjective symptoms questionnaires, saliva test | — |
Countries
Japan
Contacts
Public ContactNaoko Suzuki
ORTHOMEDICO Inc. R&D Department
Outcome results
None listed